CoChat
Sign Up
Cited by 800Antioxidant Activity and Oxidative StressRedox biology and oxidative stressParkinson's Disease Mechanisms and Treatments

The DOI matches its Crossref record; 282 of the 282 references it cites were found in a registry or an index.

Oxidative Stress in Neurodegenerative Diseases

Open access
Niedzielska, Ewa, Smaga, Irena, Gawlik, Maciej, Moniczewski, Andrzej, Stankowicz, Piotr, Pera, Joanna, Filip, Małgorzata·2016·Molecular Neurobiology
DOI 10.1007/s12035-015-9337-5PMC PMC4937091
Open this paper in CoChat — free accountOpen PDF

Abstract

The pathophysiologies of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD), are far from being fully explained. Oxidative stress (OS) has been proposed as one factor that plays a potential role in the pathogenesis of neurodegenerative disorders. Clinical and preclinical studies indicate that neurodegenerative diseases are characterized by higher levels of OS biomarkers and by lower levels of antioxidant defense biomarkers in the brain and peripheral tissues. In this article, we review the current knowledge regarding the involvement of OS in neurodegenerative diseases, based on clinical trials and animal studies. In addition, we analyze the effects of the drug-induced modulation of oxidative balance, and we explore pharmacotherapeutic strategies for OS reduction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12035-015-9337-5

Cites

282 of 282 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Generation of reactive species (based on [280–283])
Fig. 1 Generation of reactive species (based on [280–283])CC BY · PubMed Central
Fig. 2 Source of radical and OS biomarkers. 8-OHA 2,8-hydroxyadenine, HNE 4-hydroxynonenal, 5-OHC 5-hydroxycytosine, 5-OHU 5-hydroxyuracil, 8-OHdG 8-hydroxy-2′-deoxyguanosine, 8-OH-Gua 8-hydroxyguanine, AGEs advanced glycation end products, ALES advanced lipid peroxidation end products, AOPP advanced oxidation products, CTL creatol, COX cyclooxygenases, CYP cytochrome P450, ETC electron transport chain, F2-isoPs F2-isoprostanes, F4-NPs F 4-neuroprostanes, HETE hydroxyeicosatetraenoic acids, HODE hydroxyoctadecadienoic acid, HIF-1a hypoxia-inducible factor-1a, IsoF isofuran, LF lipofuscin, LOX lipoxygenases, Lyso PC lysophosphatidylcholines, MPO myeloperoxidase, NOX NADPH oxidases, NFS neurofuran, Opht A ophthalmic acid, GSSG oxidized glutathione, ox-LDL oxidized LDL, GSSG/GSH oxidized/reduced glutathione, Prxs peroxiredoxins, PC protein carbonyl, TBARS thiobarbituric acid reactive substances, TQ/TQH2 tocopherylquinone/tocopheryl hydroquinone, TAC total antioxidant capacity, Tyr tyrosines, UQ/UQH2 ubiquinone/ubiquinol, XO xanthine oxidase
Fig. 2 Source of radical and OS biomarkers. 8-OHA 2,8-hydroxyadenine, HNE 4-hydroxynonenal, 5-OHC 5-hydroxycytosine, 5-OHU 5-hydroxyuracil, 8-OHdG 8-hydroxy-2′-deoxyguanosine, 8-OH-Gua 8-hydroxyguanine, AGEs advanced glycation end products, ALES advanced lipid peroxidation end products, AOPP advanced oxidation products, CTL creatol, COX cyclooxygenases, CYP cytochrome P450, ETC electron transport chain, F2-isoPs F2-isoprostanes, F4-NPs F 4-neuroprostanes, HETE hydroxyeicosatetraenoic acids, HODE hydroxyoctadecadienoic acid, HIF-1a hypoxia-inducible factor-1a, IsoF isofuran, LF lipofuscin, LOX lipoxygenases, Lyso PC lysophosphatidylcholines, MPO myeloperoxidase, NOX NADPH oxidases, NFS neurofuran, Opht A ophthalmic acid, GSSG oxidized glutathione, ox-LDL oxidized LDL, GSSG/GSH oxidized/reduced glutathione, Prxs peroxiredoxins, PC protein carbonyl, TBARS thiobarbituric acid reactive substances, TQ/TQH2 tocopherylquinone/tocopheryl hydroquinone, TAC total antioxidant capacity, Tyr tyrosines, UQ/UQH2 ubiquinone/ubiquinol, XO xanthine oxidaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 282 references

Research works printed but not linked: 3

  1. Hirayama M, Goto S, Nakamura T, Mizutani Y, Suzuki J, Watanabe H, Sobue G (2014) Oxdative stress maker (urinary 8-hydroxy-2′-deoxyguanosine) was modified by treatment of various Parkinson’s drug. Mov Disord 29:S140
  2. Kaya Y, Ozsoy O, Onullut E, Aslan M, Yildirim FB, Anullar A (2013) Beneficial effect of melatonin treatment on substantia nigra in an experimental model of Parkinson’s disease. J Neurol Sci 30:142
  3. Snalina N, Alessenko A, Gavrilova S, Gurianova S, Prochorov A, Kononova E, Fedorova Y (2014) Memantine changes lipids spectrum and lipid peroxidation in animal brain and plasma of patients with Alzheimer’s disease. FEBS J 281:86

Cited by

Sorted by citations

See all 800

Related

Metadata

Authors
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., & Filip, M.
Affiliations
Jagiellonian University (PL)
Corresponding author
Filip, Małgorzata
ORCID
Venue
Molecular Neurobiology
Publisher
Springer Science and Business Media LLC
Published
2015-07-22
Volume
53
Issue
6
Pages
4094-4125
ISSN
  • 0893-7648 (ISSN-L)
  • 1559-1182
DOI
10.1007/s12035-015-9337-5
PMC
PMC4937091
OpenAlex
W1032629512
Cited by
800
References
282
Citations by year
2026: 40 · 2025: 90 · 2024: 103 · 2023: 80 · 2022: 88 · 2021: 103 · 2020: 92 · 2019: 78 · 2018: 60 · 2017: 39 · 2016: 19 · 2015: 4
FWCI
4.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurobiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
  • Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion)
Topics
  • Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
oxidative stress, neurodegenerative diseases, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, antioxidant defense, oxidative stress biomarkers
MeSH terms
Animals, Antioxidants, Clinical Trials as Topic, Humans, Biomarkers, Oxidative Stress, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review